SWTX vs. IOVA, DNLI, IMCR, TWST, ACLX, VCEL, RXRX, APGE, KYMR, and ADMA
Should you be buying SpringWorks Therapeutics stock or one of its competitors? The main competitors of SpringWorks Therapeutics include Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Immunocore (IMCR), Twist Bioscience (TWST), Arcellx (ACLX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), Kymera Therapeutics (KYMR), and ADMA Biologics (ADMA). These companies are all part of the "biological products, except diagnostic" industry.
Iovance Biotherapeutics (NASDAQ:IOVA) and SpringWorks Therapeutics (NASDAQ:SWTX) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, community ranking, analyst recommendations, media sentiment, profitability, risk and earnings.
SpringWorks Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Iovance Biotherapeutics presently has a consensus price target of $24.64, indicating a potential upside of 137.57%. SpringWorks Therapeutics has a consensus price target of $68.83, indicating a potential upside of 59.34%. Given SpringWorks Therapeutics' higher possible upside, equities analysts clearly believe Iovance Biotherapeutics is more favorable than SpringWorks Therapeutics.
77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 7.6% of SpringWorks Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 4 articles in the media. Iovance Biotherapeutics' average media sentiment score of 0.84 beat SpringWorks Therapeutics' score of 0.54 indicating that SpringWorks Therapeutics is being referred to more favorably in the news media.
Iovance Biotherapeutics has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500.
SpringWorks Therapeutics has a net margin of 0.00% compared to SpringWorks Therapeutics' net margin of -23,615.70%. Iovance Biotherapeutics' return on equity of -66.48% beat SpringWorks Therapeutics' return on equity.
Iovance Biotherapeutics received 468 more outperform votes than SpringWorks Therapeutics when rated by MarketBeat users. Likewise, 74.50% of users gave Iovance Biotherapeutics an outperform vote while only 68.18% of users gave SpringWorks Therapeutics an outperform vote.
Summary
Iovance Biotherapeutics beats SpringWorks Therapeutics on 10 of the 16 factors compared between the two stocks.
Get SpringWorks Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SWTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SpringWorks Therapeutics Competitors List
Related Companies and Tools